1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Epiomic Epidemiology Series: Stomach Cancer Forecast in 17 Major Markets 2016-2026

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Stomach Cancer in 17 Major Markets

Stomach cancer is a broad term encompassing tumours arising in the stomach and includes gastric carcinoma which is a malignant epithelial-origin tumour commonly developing after prolonged periods of gastritis. Stomach cancers tend to develop slowly over many years spreading in different ways. Long-term infection of the stomach with Helicobacter pylori may lead to inflammation (known as chronic atrophic gastritis) and pre-cancerous changes to the inner lining of the stomach.

This report provides the current incident population for Stomach Cancer across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Argentina, Australia, Canada, Russian, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the classifications and co-morbidities of Stomach Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main features and co-morbidities associated with Stomach Cancer include:

-History of stomach polyps or stomach lymphoma
-Family history of stomach cancer
-Colorectal cancer
-Familial adenomatous polyposis
-BRCA1/BRCA2 mutations
-Megaloblastic (pernicious) anaemia or being blood type A

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global Stomach Cancer’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the incidence of the subdivided types of Stomach Cancer and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Stomach Cancer’s incident population.
-Identify sub-populations within Stomach Cancer which require treatment.
-Gain an understanding of the specific markets that have the largest number of Stomach Cancer patients.

Table Of Contents

Epiomic Epidemiology Series: Stomach Cancer Forecast in 17 Major Markets 2016-2026
Table of Contents
-List of Tables and Figures
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography/Ethnicity
-Disease Prognosis and Clinical Course
-Key Co-morbid Conditions/ Features Associated with the Disease
-Methodology for Quantification of Patient Numbers
o Additional data available on request
-Top-Line Incidence for Stomach Cancer
-Stages and Grading of Stomach Cancer
o Location of Tumour
o Histopathology of Tumour Cells in Stomach Cancer
o Lauren Classification of Stomach Cancer
o Co-morbidity of H. Pylori infection in Stomach Cancer
-Abbreviations used in the Report
-Other Black Swan Analysis Publications
-Black Swan Analysis Online Patient-Based Databases
-Patient-Based Offering
-Online Pricing Data and Platforms
-References
-Appendix


List of Tables
-AJCC Tumour Grading Classification for Stomach Cancer
-Incidence of Stomach Cancer, total (000s)
-Incidence of Stomach Cancer, males (000s)
-Incidence of Stomach Cancer, females (000s)
-AJCC Stage at diagnosis for Stomach cancer patients, total (000s)
-Location of tumour cells in Stomach Cancer patients, total (000s)
-Major histopathological type of Stomach Cancer, total (000s)
-Lauren Classification of Adenocarcinoma subtypes in SC patients, total (000s)
-H. Pylori infection in Stomach cancer, total (000s)
-Abbreviations and Acronyms used in the report
-USA Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-USA Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-France Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-France Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Germany Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Germany Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Italy Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Italy Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Spain Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Spain Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-United Kingdom Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-United Kingdom Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Brazil Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Brazil Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Japan Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Japan Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-India Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-India Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Mexico Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Mexico Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Turkey Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Turkey Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Argentina Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Argentina Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Australia Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Australia Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Canada Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Canada Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Russia Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Russia Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-Saudi Arabia Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-Saudi Arabia Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
-South Africa Incidence of Stomach Cancer by 5-yr age cohort, males (000s)
-South Africa Incidence of Stomach Cancer by 5-yr age cohort, females (000s)
?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
European Cancer Therapies Market - Growth, Trends and Forecasts (2017 - 2022)

European Cancer Therapies Market - Growth, Trends and Forecasts (2017 - 2022)

  • $ 3850
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Europe market for Cancer therapy market has been estimated at USD 6.024 billion for the year 2014 and is projected to reach USD 12.54 billion by the end of 2020 at a CAGR of 13 % during the forecast ...

Asia-Pacific Cancer Therapy Market - Growth, Trends, and Forecasts (2017 - 2022)

Asia-Pacific Cancer Therapy Market - Growth, Trends, and Forecasts (2017 - 2022)

  • $ 3850
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Asia-Pacific market for cancer therapy was estimated at USD 3.65 billion for the year 2014 and is projected to reach USD 7.97 billion by the end of 2020 at a CAGR of 13.9 % during the forecast period ...

2017-2021 France Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 France Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 4350
  • Industry report
  • February 2017
  • by Venture Planning Group

Highlights Comprehensive 585-page analysis of the French tumor marker testing market.Major issues pertaining to the French laboratory practice, as well as key economic, regulatory, demographic, social ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Cancer and Colorectal Cancer Statistics in the UK - Forecast

  • March 2017
    91 pages
  • Cancer  

    Colorectal Canc...  

    Health Care Pro...  

  • United Kingdom  

View report >

Cancer Statistics in the US

  • March 2017
    19 pages
  • Cancer  

  • United States  

View report >

Related Market Segments :

Stomach Cancer

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.